Completed NA INTERVENTIONAL 2-arm NCT02419963

Analyzing IBS to Identify Biomarkers and Microbiome Signatures

A New Dimension in Modeling Irritable Bowel Syndrome (IBS) to Elucidate Novel Diagnostic Biomarkers and Microbiome Signatures

Sponsor: Mayo Clinic

Conditions Diarrhoea Predominant Irritable Bowel Syndrome IBS

Interventions Blood Sample Stool Sample endoscopy for tissue biopsy

Updated 7 times since 2017 Last updated: Jul 5, 2017 Started: May 31, 2015 Primary completion: Dec 12, 2016 Completion: Dec 12, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Diarrhoea Predominant Irritable Bowel Syndrome and IBS, this trial is completed. The trial is conducted by Mayo Clinic and has accumulated 7 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Aug 2017 — Jun 2018 [monthly]

Completed NA

Status: Recruiting → Completed · Phase: EARLY_PHASE1 → NA

▶ Show 2 earlier versions

Feb 2017 — Aug 2017 [monthly]

Recruiting EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting Phase 0

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayo Clinic

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Scottsdale, United States